前哨淋巴结活检改善黑色素瘤生存:系统综述与荟萃分析
BACKGROUND: It is unproven whether sentinel node biopsy (SNB) for people with cutaneous melanoma improves survival. This study aimed to establish whether there is a reduction in the risk of death from melanoma after SNB.…
核心结论
- 接受前哨淋巴结活检的黑色素瘤患者黑色素瘤死亡风险和复发风险均显著降低,敏感性分析支持结果的稳健性。
研究设计与样本
- 系统综述与荟萃分析,检索Medline、Embase、Cochrane CENTRAL和ClinicalTrials.gov(截至2025年1月8日),从1560条记录中纳入60项研究,其中13项研究(40 287例参与者)报告调整风险比进入荟萃分析。
临床怎么用
- 对于成人皮肤黑色素瘤患者,SNB可显著降低黑色素瘤死亡和复发风险,支持其作为改善生存的干预措施。
局限性
- 10年死亡风险分析仅基于2项研究的三项估计,异质性较高(I2 41%),结果需谨慎解读。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: It is unproven whether sentinel node biopsy (SNB) for people with cutaneous melanoma improves survival. This study aimed to establish whether there is a reduction in the risk of death from melanoma after SNB. METHODS: This systematic review and meta-analysis involved searches of Medline, Embase, Cochrane CENTRAL, and ClinicalTrials.gov (up to Jan 8, 2025) using terms for melanoma, SNB, and survival. Studies were included if they reported survival in adults (ie, aged ≥18 years) with melanoma who underwent SNB relative to those who did not, and excluded studies without these data, because survival risk in people with melanoma could not be calculated. Duplicate title review (by GJW and CAG) and data extraction (by GJW and MBW) were performed. The primary outcome was death from melanoma. Risk of bias was assessed using the Newcastle-Ottawa and Cochrane Collaboration tools. This study was registered with PROSPERO (number CRD4203494674). FINDINGS: From 1560 screened records, 60 studies were eligible for analysis. After the exclusion of one study with high selection bias meta-analysis, 13 studies (40 287 participants) reporting an adjusted risk were analysed and showed a significantly reduced risk of death from melanoma for people who underwent SNB: hazard ratio (HR) 0·86 (95% CI 0·81-0·92, p<0·0001), with low heterogeneity (I2 16%). Sensitivity analyses confirmed that this result was not dependent on any single study or on the use of systemic therapy. A similar result was obtained from the analysis of the five studies (27 540 participants) that reported 5-year risk of death from melanoma: HR 0·84 (95% CI 0·78-0·90, p<0·0001) with low heterogeneity (I2 15%). A 10-year risk of death from melanoma was reported in two studies with three estimates: 0·87 (0·71-1·06; p=0·17) and with greater heterogeneity (I2 41%). From nine studies (11 625 participants) reporting an adjusted risk of recurrence, the HR was 0·71 (95% CI 0·66-0·76, p<0·0001) with low heterogeneity (I2 23%). INTERPRETATION: This meta-analysis showed that people with melanoma who underwent SNB had a significantly reduced risk of death from melanoma and recurrence compared with those who did not. These findings are consistent with the only published randomised controlled trial and were robust on sensitivity analyses, indicating that SNB confers true survival and recurrence benefits. FUNDING: None.
引用
- Varey AHR, Weitemeyer MB, Gjorup CA, et al. Assessment of survival benefit from sentinel node biopsy for melanoma: a systematic review and meta-analysis. Lancet Oncol. 2026. PMID: 41796592. doi:10.1016/S1470-2045(26)00026-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。